TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01481493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT061
Description: subcutaneous administration of the monoclonal antibody BT061

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection of placebo
Study: NCT04165057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal muscle tension management
Description: including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
Study: NCT02695407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 days cannulation
Description: assessment of artery stenosis after 3 days of artery cannulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 days cannulation
Description: assessment of artery stenosis after 5 days of artery cannulation
Study: NCT00942851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-Hexapeptide Topical Treatment
Description: AH-8 containing topical treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical treatment NOT containing AH-8
Study: NCT02688790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Study: NCT05948488

Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires focus on anxiety, fear and quality of life.
Study: NCT03475238

Intervention type: PROCEDURE
Intervention: Nursing care
Description: The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
Study: NCT01812915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cylindrical-shape cuff ETT (Group C)
Description: Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tapered-shape cuff ETT (Group T)
Description: Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
Study: NCT00576537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunotherapy
Description: Patients will receive four vaccines.
Study: NCT01578265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets USP 8 mg
Description: 8 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: 8 mg tablet once a day
Study: NCT05408364

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic or natural yoghurt
Description: Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic or natural yoghurt
Description: Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP
Description: Scalling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP
Description: Scalling and root planing
Study: NCT03658980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
Study: NCT02970084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutraceutical product based on vitamin K2 (PLAK2)
Study: NCT02074514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02888054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablet
Study: NCT01876459

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological tests

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological tests
Study: NCT04328116

Intervention type: DEVICE
Intervention: Dental Implants
Description: Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
Study: NCT02888054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Study: NCT03515343

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening colonoscopy according to resect-and-discard strategy
Description: This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening colonoscopy according to resect-and-discard strategy
Description: This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
Study: NCT03626987

Intervention type: DIAGNOSTIC_TEST
Intervention: mass spectrometry (MALDI-TOF)
Description: The determination of the protein composition of the bacterial spectrum
Study: NCT01390077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
Study: NCT02581631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Study: NCT03001076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Description: bempedoic acid 180 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: ezetimibe 10 mg tablet
Study: NCT02888054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Study: NCT03001076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: ezetimibe 10 mg tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study: NCT01551459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
Study: NCT00660452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Staloral
Description: Sublingual immunotherapy with Staloral dust mites solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Staloral
Description: Sublingual immunotherapy with Staloral dust mites solution
Study: NCT04200300

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study: NCT02643277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging
Description: The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
Study: NCT03310567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat + pembrolizumab
Description: Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
Study: NCT04394325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital information tool
Description: The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
Study: NCT01152671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: single oral dose
Study: NCT01814540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Milk Oligosaccharide
Description: The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Milk Oligosaccharide
Description: The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Glucose Polymer
Study: NCT04016974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily throughout the treatment period (day 1 to 84)
Study: NCT01729195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A ciprofloxacin containing bioabsorbable PLGA bone screw
Description: The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
Study: NCT02859298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Cervix Polarimetric Imaging
Description: Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Cervix Polarimetric Imaging
Description: Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
Study: NCT01551459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
Study: NCT04394468

Intervention type: DEVICE
Group type: OTHER
Intervention: PlasmaJet
Description: Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
Study: NCT05377437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Language Processing
Description: Natural Language Processing: classification and regression tasks.
Study: NCT02235389

Intervention type: DRUG
Intervention: Alteplase (Actilyse)

Intervention type: DRUG
Intervention: Standard therapy
Study: NCT01147276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin (50 mg BID) in four weeks
Study: NCT02878889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study: NCT02773563

Intervention type: OTHER
Intervention: EUS with air insufflation
Description: Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation

Intervention type: OTHER
Intervention: EUS with CO2 insufflation
Description: Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
Study: NCT01038739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 3 g per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 1.5 g per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study: NCT04113694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Infusion Set
Description: Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
Study: NCT02528032

Intervention type: OTHER
Group type: OTHER
Intervention: Echographic evaluation of heart function
Description: Echocardiographic data collection and analysis, not fully exploited at present
Study: NCT00608179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide
Description: Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: hypoglycemic glucose clamp procedure -120 minutes
Study: NCT04243278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: 81 mg of low dose aspirin PO for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo PO for 6 months
Study: NCT00265434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmozyme
Study: NCT00888927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
Study: NCT02977273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin/100% Portion
Description: Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin/150% Portion
Description: Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thick/100% Portion
Description: Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thick/150% Portion
Description: Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
Study: NCT04104828

Intervention type: BIOLOGICAL
Intervention: Allergovit
Description: Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis

Intervention type: BIOLOGICAL
Intervention: Polvac
Description: Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis

Intervention type: BIOLOGICAL
Intervention: Pollinex Quattro
Description: Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
Study: NCT00777088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Description: 1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
Study: NCT00265434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pulmozyme
Study: NCT02247973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Intravenous administration of up to 1\~2x10\^6 MSCs per kg,for 2 times,d0 and d14
Study: NCT05029492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie diet
Description: Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral manipulation with diet
Description: Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).